Ken Griffin Bridge Bio Pharma, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 352,800 shares of BBIO stock, worth $8.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
352,800
Previous 322,400
9.43%
Holding current value
$8.25 Million
Previous $13 Million
16.19%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding BBIO
# of Institutions
284Shares Held
170MCall Options Held
7.41MPut Options Held
2.61M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$726 Million40.56% of portfolio
-
Viking Global Investors LP25.1MShares$587 Million2.96% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$309 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$245 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$142 Million64.21% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.47B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...